Hints and tips:
Showing results for Sanofi S.A.
Related Special Reports
...Sanofi’s operating income fell 5.2 per cent at the end of last year as adverse currency rates and generic competition with multiple sclerosis pill Aubagio hit sales....
...Sanofi insists it has 12 possible blockbusters in the pipeline, with a collective peak sales potential of €33bn to €60bn....
...The business accounts for just over a tenth of Sanofi’s total sales....
...Sanofi chief executive Paul Hudson has admitted he could have done a better job explaining aspects of a multibillion-euro investment plan to shareholders, ahead of a meeting where he will try to sell them...
...Sanofi has since restructured its consumer division as a standalone business within the company....
...Sanofi said a split of the consumer unit could take place as early as the end of next year, most likely through a listing in Paris....
...The Granolas as a group have climbed 18 per cent over the past 12 months beating the Stoxx 600’s 7.5 per cent rise over the same period....
...For some pharma groups, notably Sanofi of France, the pandemic was a time of embarrassing and very public underperformance....
...Goldman Sachs gave it a go with the ‘Granolas’ or, more accurately, GRANNNLLASS: GSK, Roche, ASML, Nestlé, Novartis, Novo Nordisk, L’Oréal, LVMH, AstraZeneca, SAP, and Sanofi....
...The S&P 500 was headed for a record closing high as traders assessed US inflation data that unexpectedly increased last month....
...Stock markets in Asia were muted in early trading on Wednesday despite the US S&P 500 closing at a record high....
...The S&P 500 closed at a record high, even after US inflation data showed price pressures in the world’s largest economy were not cooling as quickly as Wall Street expected....
...French rival Sanofi is fighting a similar battle despite upping R&D spend by around €700mn this year as it works to reduce its reliance on its asthma and eczema treatment Dupixient....
...Sanofi raised its full year earnings guidance after sales of its immunology drug Dupixent soared by more than a third in the second quarter....
...worth less than the face value of their debt, in a scenario that can help borrowers and private equity sponsors avoid expensive bankruptcy proceedings....
...But on Tuesday night, the company announced it had failed to reduce relapse rates for MS patients compared with teriflunomide, which is produced by rival Sanofi....
...But for F1, the Red Bull drama is a major, unwanted distraction. The head of F1’s governing body told the FT last week it was “damaging the sport”....
...S&P Global Ratings has made a hefty revision to its US economic forecast, citing a bigger than expected expansion at the end of last year and a labour market that looks more solid than a month ago....
...In the US, the benchmark S&P 500 had gained 0.1 per cent, and the tech-heavy Nasdaq Composite rose 1.1 per cent....
...One reason for the modest outlook, Buffett writes, is that his company is so big now — 6 per cent of the S&P 500’s total shareholders’ equity — that there are no companies in the US or abroad that are (a...
...The benchmark S&P 500 index rose 0.5 per cent in a broad rally, with tech and real estate the best-performing sectors. Nearly two-thirds of stocks closed higher....
...It is not a stretch for Sanofi, with a net debt-to-ebitda ratio of 0.6 according to S&P Capital IQ....
...The Nobel and Pulitzer Prize-winning author Pearl S Buck amassed a personal library that fills two rooms of her 19th-century Pennsylvania farmhouse....
International Edition